tag wales 
pharmaphorum
NOVEMBER 16, 2021
NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharma’s Ontozry.
pharmaphorum
APRIL 20, 2021
The cost-effectiveness agency has said that anti-CD20 antibody Kesimpta (ofatumumab) can be prescribed via the NHS in England and Wales as a treatment for adults with RMS with active disease, as either a first-line therapy or after alternative drugs have been tried.
pharmaphorum
NOVEMBER 19, 2021
million price tag make it is the most expensive treatment ever approved for NHS funding. Roche said it is in discussions with the relevant authorities in Wales and Northern Ireland to try to extend the NICE guidance on risdiplam to these countries as quickly as possible.
Expert insights. Personalized for you.
96 
Let's personalize your content